A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFN alpha-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.

Trial Profile

A Phase I-II, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study of Neovacs' IFN alpha-Kinoid in Adult Subjects With Systemic Lupus Erythematosus.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Interferon alpha kinoid (Primary) ; Montanide ISA-51
  • Indications Glomerulonephritis; Lupus nephritis; Systemic lupus erythematosus
  • Focus Adverse reactions; First in man
  • Sponsors Neovacs
  • Most Recent Events

    • 28 Jun 2016 Results of extended follow-up data published in the Rheumatology
    • 09 Sep 2015 According to Neovacs media release, company has presented extended follow-up data at the 11th International Congress on Systemic Lupus Erythematosus (SLE).
    • 17 Sep 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top